Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet
Por um escritor misterioso
Descrição
Dual Antiplatelet Therapies and Causes in Minor Stroke or
Design and Preclinical Characterization Program toward Asundexian
Pharmacology and Clinical Development of Factor XI Inhibitors
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
Safety and efficacy of factor XIa inhibition with milvexian for
Factor XI inhibitors in patients with cardiovascular disease and a
JCM, Free Full-Text
Safety and efficacy of factor XIa inhibition with milvexian for